Structure via PubChem · Public domain (PubChem)
ixazomib
Sign in to saveIxazomib (trade name Ninlaro) is a drug for the treatment of multiple myeloma, a type of white blood cell cancer, in combination with other drugs. It is taken by mouth in the form of capsules.
Chemical data
- Formula
- C14H19BCl2N2O4
- Molecular weight
- 361 g/mol
- IUPAC name
- [(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]boronic acid
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 3
- Molecule type
- Small molecule
- Indications
- neoplasm, lymphoma, renal cell carcinoma, multiple myeloma
via ChEMBL · EBI
Research
756 papers- Ixazomib.2006
- Ixazomib.2012
- Ixazomib - the first oral proteasome inhibitor.Leukemia & lymphoma · 2019
- Ixazomib.2026
- Ixazomib for the treatment of multiple myeloma.Expert opinion on pharmacotherapy · 2018
via PubMed
Wikidata facts
- Mass
- 360.081
Show 4 more facts
- chemical formula
- C₁₄H₁₉BCl₂N₂O₄
- isomeric SMILES
- B([C@H](CC(C)C)NC(=O)CNC(=O)C1=C(C=CC(=C1)Cl)Cl)(O)O
- canonical SMILES
- B(C(CC(C)C)NC(=O)CNC(=O)C1=C(C=CC(=C1)Cl)Cl)(O)O
- World Health Organisation international non-proprietary name
- ixazomib
Sources (8)
via Wikidata · CC0
~7 min read
Article
11 sectionsContents
- Medical uses
- Pregnancy and breastfeeding
- Side effects
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- Chemistry
- History
- Research
- References
Ixazomib (trade name Ninlaro) is a drug for the treatment of multiple myeloma, a type of white blood cell cancer, in combination with other drugs. It is taken by mouth in the form of capsules.
Common side effects include diarrhea, constipation and low platelet count. Like the older bortezomib (which can only be given by injection), it acts as a proteasome inhibitor, has orphan drug status in the US and Europe, and is a boronic acid derivative.